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Abstract
Background: There has been an exponential growth in the number of clinical research studies regarding exercise
training in multiple sclerosis, and literature reviews and meta-analyses have documented the many benefits of
exercise training. This research further requires careful review for documenting the safety of exercise training in
multiple sclerosis, as clarity on safety represents a major hurdle in the clinical prescription of exercise behaviour.
Objectives: To enhance understanding of the feasibility of exercise in multiple sclerosis, we (1) provide a protocol
of a systematic review and meta-analysis that summarises rates and risks of clinical relapse, adverse events (i.e., an
unfavourable outcome that occurs during the intervention delivery time period), and serious adverse events (i.e., an
untoward occurrence that results in death or is life threatening, requires hospitalisation, or results in disability
during the intervention delivery time period), as well as retention, adherence, and compliance, from randomised
controlled trials of exercise training in persons with multiple sclerosis; and (2) identify moderators of relapse,
adverse events, and serious adverse event rates.
Methods: Eight field-relevant databases will be searched electronically. Studies that involve a randomised
controlled trial of exercise training (with non-exercise, non-pharmacological, comparator), report on safety
outcomes, and include adults with multiple sclerosis will be included. Rates and relative risks of the three primary
outcomes (relapse, adverse event, and serious adverse event) will be calculated and reported each with standard
error and 95% confidence interval. Random-effects meta-analysis will estimate mean population relative risk for
outcomes. Potential sources of variability, including participant characteristics, features of the exercise stimulus, and
comparison condition, will be examined with random-effects meta-regression with maximum likelihood estimation.
Discussion: The results from this systematic review and meta-analysis will inform and guide healthcare
practitioners, researchers, and policymakers on the safety of exercise training in persons with multiple sclerosis.
Where possible, we will identify the impact of exercise type, exercise delivery style, participant disability level, and
the prescription of exercise guidelines, on the safety of exercise training. The result will identify critical information
on the safety of exercise in persons with multiple sclerosis, while also identifying gaps in research and setting
priorities for future enquiries.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: y.learmonth@murdoch.edu.au
1Discipline of Exercise Science, Murdoch University, Murdoch, WA, Australia
2Perron Institute for Neurological and Translational Science, Perth, WA,
Australia
Full list of author information is available at the end of the article
Learmonth et al. Systematic Reviews          (2021) 10:208 
https://doi.org/10.1186/s13643-021-01751-0
Systematic review registration: PROSPERO 2020 CRD42020190544
Keywords: Multiple sclerosis, Exercise-training, Relapse, Adverse event, Serious adverse event
Background
Multiple sclerosis (MS) is a chronic, immune-mediated
disease of the central nervous system (CNS) with no
known cure [1]. There has been an estimated 10% in-
crease in the global prevalence of MS in the last two de-
cades [2], with estimates indicating MS now affects over
2.8 million people globally [3], with one million cases in
the USA alone [4]. MS is the most common non-
traumatic disabling disease among young adults and is
more common in females [5]. The underlying cause of
the disease is unknown, and the disease follows a
relapsing-remitting clinical trajectory in the majority of
cases. MS commonly results in cumulative and heteroge-
neous physical and cognitive disability, as well as debili-
tating symptoms such as fatigue, depression, and pain
[6]. The health burden is high such that the 2016 Global
Burden of Disease study reported that over 1.1 million
disability-adjusted life-years were attributable to MS [2].
The burden of MS has both personal and societal im-
pacts, and this extends into participation in optimal
health behaviours, such as exercise participation. Up-
wards of 80% of persons with MS do not engage in suffi-
cient amounts of exercise necessary for health-related
benefits [7]. Exercise training represents the salient ap-
proach to symptom management, and safe approaches
to increase and maintain exercise practices should be
promoted among persons with MS throughout the dis-
ease trajectory [8, 9].
Optimal health and wellness are of high priority for
people with MS [10, 11], and persons with MS can
achieve optimal health through positive health behav-
iours, particularly participation in exercise. Exercise is
commonly included in rehabilitation programmes ad-
dressing the functional impairments associated with
MS [12]; exercise is widely considered to be an essen-
tial strategy in the clinical management of MS [13].
Over three decades of scientific enquiry have estab-
lished the many health benefits of exercise training in
persons with MS [14]. Systematic reviews and meta-
analysis have concluded that exercise training can im-
prove physical fitness and walking mobility [15, 16],
balance [17], cognition [18], fatigue [19], depressive
symptoms [20–22], and quality of life [19]. There is
evidence indicating that exercise has a positive effect
on the hippocampus [23, 24], sleep quality [25, 26],
and cardiovascular and metabolic comorbidity [27,
28]. The volume and quality of research output on
exercise in MS populations has increased substantially
in recent years [9].
There further is a shift in the clinical landscape sur-
rounding exercise prescription in MS. This is based on
the first clinical exercise guidelines for persons with
mild-to-moderate MS that were published in 2013 [19,
29], and have now been updated and expanded [30]. Im-
portantly, these guidelines have been endorsed by inter-
national MS societies [8, 31], yet we still know very little
about the safety profile of exercise among persons with
MS. This is particularly important, as healthcare pro-
viders have seemingly been reluctant in prescribing exer-
cise training for clinical management of MS [32], with
evidence indicating that this may, in part, be because
there is limited comprehensive understanding of the risk
profile of this behaviour [13]. The recent surge in exer-
cise training studies in MS [9] further underscores the
need to identify the safety profile on this salient inter-
vention in MS.
Relapse risk, adverse events (AE), and serious adverse
events (SAE) [33, 34] indicate the construct of safety in
MS clinical study, and we describe these terms in Table 1.
To date, only three reviews have considered the safety of
exercise training for MS [35–37]. The most comprehen-
sive included 26 RCTs published up until November 2013
[35]. That study reported that people with MS receiving a
form of exercise intervention had lower rates of relapse
equating to approximately 27% lower relapse rate for exer-
cise training versus non-exercise control conditions. Not-
ably, the rate of other AE across studies was higher in the
exercise as represented by a 67% higher risk of AE from
exercise. In terms of AE, 22 of the 26 RCTs recorded
dropout rate, and this is important as another indicator of
intervention feasibility; the mean dropout rate across stud-
ies was 15.2% for control group participants and 15.5% for
exercise training participants.
Another review included safety outcomes as a sub-
analysis during a review of the efficacy of physical inter-
ventions in MS [36]. That systematic review included
three additional studies to the focal review in 2014, and
authors provided a narrative commentary of AE, relapse,
and dropout rate. One more recent systematic review fo-
cused on high-intensity aerobic interval training in MS,
and inclusive of studies up to September 2017 noted the
reporting of no AE in six of the seven included studies
[37]. However, the authors did not provide an analytical
review of safety constructs. One other systematic review
and meta-analysis of AE reported AE and SAE across 16
different health conditions, with MS investigated as part
of the Neurological subgroup [38]. The authors estab-
lished that in neurological conditions, there is a
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Table 1 Items for extraction and definition of terms used in this systematic review
Extractions format and definitions
Study details
Author First author surname
Year Year published
Title Title of publication
Country Corresponding author affiliation
Funding source From text
Conflict of interest declared Reported as yes, no, other
Clinical trial registry ID From text
Methods
Study design RCT, cluster RCT, other
Study aims From text
Years of study recruitment Years
Retention strategy employed Described where relevant as remumeration or other method
Participants
Age Mean (standard deviation), median (range)
Gender Male, female, other/unspecified
Race/ethnicity Described where possible from text
Socioeconomic status Employment status, income, level of education, or similar
MS type Type of MS of participants; relapse remitting, primary progressive, secondary progressive, progressive relapsing
Years diagnosed with MS Mean (standard deviation), median (range)
Disability level* Described where possible using Expanded Disability Status Scale or Patient Determined Disease Steps. Means (std)
or median (range) will be reported. Other descriptors of disability will be reported.
Described where possible as mild, moderate, or severe disability. Mild disability is usually categorised as EDSS <4.5
or PDDS 0–3, moderate disability is usually categorised as EDSS 4.5–6 or PDDS 4–5, and severe disability is usually
categorised as EDSS 6.5–9.5 or PDDS 7–8.
Inclusion/exclusion criteria From text
Intervention
Frequency Sessions/Wk
Intensity (aerobic exercise) Described where relevant as light, moderate, vigorous
Light intensity exercise is usually between 9 and 11 on the Borg 6 to 20 RPE scale, or 1–2 on the Borg 1–10 RPE
scale.
Alternatively, light intensity exercise is 30–39% VO2R or HRR [60].
Vigorous intensity exercise is usually between 14 and 17 on Borg’s 6–20 RPE scale.
Alternatively, vigorous intensity exercise is 60–89% VO2R or HRR [60]
Type* Described where possible as aerobic, resistance, flexibility, balance, neuromotor, combined, aerobic interval training,
or other
Aerobic exercise training is a type of exercise in which the body’s large muscles move rhythmically for sustained
periods [61]. Minimal guidelines for aerobic exercise are two 30-min sessions per week [19, 30].
Resistance exercise training refers to activities where muscles work or hold against an applied force or weight to
improve muscular fitness; traditional resistance training incorporates progressions and rest intervals [62, 63]. Minimal
guidelines for resistance exercise are two sessions per week comprising 5–10 exercises [19, 30].
Flexibility exercise training considers activities that are designed to preserve or extend range of motion [61].
Balance training refers to activities designed to increase lower body strength and reduce the likelihood of falls [61].
Neuromotor or multicomponent exercise training combines different motor skills (e.g., balance, coordination, gait,
agility, and proprioceptive training) [62, 64]; this is not combined exercise training.
Combined exercise is a combination of different exercise types within an intervention (e.g., aerobic exercise and
resistance exercise).
Aerobic interval involves varying the exercise intensity at fixed time interval during a single exercise session [60].
Session time Session min/d
Exercise prescription Described where possible as modality of exercise, equipment, sets and repetition, and rest periods. Detail of
progression through programme will be identified.
Meeting minimum
guidelines dose*
Identified from the frequency of aerobic exercise (2/wk) and resistance exercise (2/wk) sessions, the intensity and
time of aerobic exercise (moderate intensity, 30 min [19, 29]), and the intensity of resistance exercise (one to four
Learmonth et al. Systematic Reviews          (2021) 10:208 Page 3 of 10
Table 1 Items for extraction and definition of terms used in this systematic review (Continued)
Extractions format and definitions
sets of 10 to 15 repetitions at 10–15 repetitions maximum [19, 29])
Programme duration Number of weeks
Facilitator qualifications and
training
Described where possible according to clinical qualification and/or studying qualification
Mode of delivery* Described where possible as supervised, independent, or remotely supervised
Supervised programmes are in person and supervised by a researcher trained in exercise rehabilitation, an allied
healthcare professional, or students trained in exercise rehabilitation on allied healthcare. We will extract data on
the setting where the exercise training is supervised.
Independent programmes are completed in the participant’s community or home, and a researcher or health
professional does not supervise the intervention in real-time. Information may be provided via mail or asynchron-
ously via telehealth. Participants may provide feedback on intervention adherence to the researchers/health profes-
sionals. Synchronous communication is limited between the researcher/health professional team and the
participant.
Remotely supervised programmes are completed in the participant’s community or home; asynchronous
telecommunication to provide supervision, programming, or intended advice is an important study construct. We
will extract data on the setting where the exercise training is supervised.
Description of comparator Control condition will be categorised. We will extract data on the instruction provided to control participants,
example categories include “usual activity”, “usual activity + social programme”, “education”
Primary outcomes of interest Only events occurring during the intervention period will be considered
Relapse Relapse is an acute onset of new or worsening neurological symptoms, lasting over 24 h [65]
Will be reported on using terms “relapse” or a combination of words pertaining to “increase symptoms”, “symptom
exacerbation”.
From text, distinction of increased symptoms indicating a relapse will be determined from the text.
Adverse event*
(Adverse effects)
An adverse event is an unfavourable outcome that occurs during or after the intervention [33]; we consider AE to
have a causal relationship, or not, to the intervention. We will focus on events that occur within the intervention
delivery time-period (e.g., the weeks the intervention is delivered).
Will be reported on terms “adverse event”, “adverse effect”, or “injury”, “illness”, “falls”, “joint pain”, “upper respiratory
tract infection”, “sprains”, “strains”, “muscle pain”, “symptom exacerbation”
Described where possible as musculoskeletal, respiratory illness, fall, cardiovascular, other
From text, distinction between adverse event and adverse effect will be determined from text. We will identify the
presence of causal language for example “engagement in intervention led to…” or “event was unrelated to
participation in the intervention” to assist in our identification of adverse effects.
Serious adverse event*
(Serious adverse effects)
A SAE is an untoward occurrence that results in death or is life-threatening, requires hospital admission, or results in
significant or permanent disability that occurs during or after the intervention [34]; we consider SAEs with a causal
relationship, or not, to the intervention. We will focus on events that occur within the intervention delivery time-
period (e.g., the weeks the intervention is delivered).
Will be reported on terms “serious adverse event”, “heart attack”, “myocardial infarction”, “stroke”, “pulmonary
embolism”, “fracture”, and “dislocation” to assist in our identification of adverse effects.
Described where possible as musculoskeletal, respiratory illness, fall, cardiovascular
From text, distinction between serious adverse event and serious adverse effect will be determined from text. We
will identify the presence of causal language for example “engagement in intervention led to…”
Retention rates Retention is the completion of outcome measurements following the intervention.
Will be reported on number completed first post-intervention follow-up data collection/number recruited
Intervention adherence rate Adherence is the extent to which the participant follows the intervention corresponding with the agreed
recommendations of the study [66]; we consider adherence as attendance to exercise sessions.
Will be reported on number of attended exercise sessions for the intervention.
From text: terms of attendance to exercise sessions for the intervention, e.g., “attendance”, “journal”, “diary”, aspects
reported will include “Frequency”, “intensity”, “modality”, “duration”
Intervention compliance rate Compliance is the extent to which the participant exercise behaviour matches the agreed recommendations of the
study [66], we consider compliance as the completion of the prescribed exercise programme.
Will be reported on compliance and completion of the prescribed programme.
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decreased risk of non-serious AE when participating in
exercise training interventions. Our review in 2014 iden-
tified a need for more transparent recording and report-
ing of safety outcomes in MS exercise training studies
[39], and we highlighted a lack of transparent reporting
of exercise training protocols and variability in exercise
prescriptions. Our contemporaries recently noted that
reporting of training protocols is improving [36]. How-
ever, those researchers did not take analytical ap-
proaches to compare safety between and across exercise
interventions. There has been no clear distinction be-
tween SAE and non-serious AE. Such distinctions are of
high importance as we judge the severity of any event
and focus on the likely attribution exercise training may
have on relapse, SAE, or AE in MS. A review of safety in
randomised controlled exercise training studies in MS
will allow fair comparison, and our planned review will
focus on relapse, SAE, and AE as primary outcomes.
Today, alongside the increasing number of clinical
exercise trials in MS [9], there has been a move to-
wards exercise prescription at vigorous intensities,
through the medium of interval training [37] (defined
in Table 1), as an example. There is an urgent need
to build on what is already known about the safety of
exercise in MS, particularly to closely focus on the
contemporary research published after that important
review. To date, the focus on intervention characteris-
tics, such as exercise type, delivery style (e.g., super-
vised, independent, or remotely supervised),
participant disability level (e.g., mild, moderate, or se-
vere, as determined via, e.g., the Expanded Disability
Status Scale [1]), or the prescription of exercise con-
sistent with minimal exercise guidelines for persons
with MS [19, 29], have not been considered in terms
of safety. Establishing the safety profile of exercise in-
terventions at this level will offer greater clarity in
intervention delivery and assist with providing data
on the feasibility of the exercise guidelines.
The comprehensive review of the safety of exercise
training must further include information on retention
rates, alongside adherence to attending the intervention
and compliance with the prescribed exercise of the inter-
vention. Recently, one study has taken a meta-analytical
approach to identify adherence and study completion
rates in 41 MS exercise training studies. That study
identified a pooled estimate of adherence at 0.73 (CI
0.68–0.78) when including participants who did not
complete the study [40]. The authors indicated that fur-
ther work is warranted to identify the influencing factors
on retention and adherence; our review will provide es-
sential data on the relationship between outcomes of
safety and retention, adherence, and compliance to exer-
cise interventions, and therefore, address the request of
these authors.
The proposed systematic review builds on our previ-
ous review considering publications from 2013 onward
to (a) quantify the relative risk of relapses, AE, SAE, and
dropout (i.e., retention rate) for exercise conditions com-
pared to non-exercise comparison conditions; and (b)
provide a proxy measure of participation with exercise
training among persons with MS by considering inter-
vention retention, adherence, and compliance. Second-
ary aims will include exploration of potential sources of
variability in overall relative risk, including variables of
theoretical, practical, and/or prior empirical relation to
exercise interventions, such as (c) exercise types, (d) ex-
ercise delivery styles, and (e) disability levels (defined in
Table 1 and based on established disability cut-points
[41]), and (f) prescription of exercise training consistent
with the minimal exercise guidelines for persons with
mild to moderate MS [19, 29], and we will examine year
of publication as a variable in the overall effect. We will
further identify the reporting of rates of relapse, rates of
adverse effects (refer to Table 1, these are AE directly re-
ported as attributable to the intervention), serious ad-
verse effects (refer to Table 1, these are AE directly
Table 1 Items for extraction and definition of terms used in this systematic review (Continued)




Completeness of follow-up Yes/no







Note: VO2R VO2 reserve, HRR heart rate reserve, EDSS Expanded Disability Status Scale, PDDS patient-determined disease steps
*Considered for subgroup analyses
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reported as attributable to the intervention), retention,
adherence to attending the exercise training, and com-
pliance with the prescribed exercise training in rando-
mised controlled trials.
Methods
The protocol will adhere to the Preferred Reporting
Items for Systematic review and Meta-Analysis Protocol)
statement [42]. An original review by the research team
[35] was a basis for the current review. The protocol for
the review is registered with the International Prospect-
ive Register of Systematic Reviews (PROSPERO 2020
CRD42020190544). As detailed in the authors’ previ-
ously published systematic reviews [43–45], standard
methods will be used for data extraction, data synthesis
and meta-analysis, and meta-regression analysis. In
addition, the Participants, Interventions, Comparisons,
and Outcomes (PICO) strategy was adapted to suit the
scope of the review and used to guide the search strategy
[46]. In brief, and described in detail in the search strat-
egy and Table 1, the terms were persons with Multiple
Sclerosis (Participants) and Exercise training (Interven-
tion). The comparison is non-exercise and non-
pharmacological comparator, and relapse, AE, and SAE
are the main outcomes.
Eligibility criteria
The inclusion criteria are as follows: a randomised con-
trolled trial (RCT) design with reporting of safety out-
comes overall and per condition during the study; adults
(aged 18 years or above) with multiple sclerosis; an
intervention type which meets the definition of exercise
training [47]. All non-active/non-exercise control condi-
tions will be considered, for example, “usual activity,
non active education programme”. Further, data derived
from articles included in our original review [35] will be
included.
The following exclusion criteria will be applied: studies
not written in English, non-human participants, physical
interventions which are primarily sedentary (e.g., manual
therapy, breathing exercises, pelvic floor exercises), con-
trol interventions which are pharmacology based.
Search strategy and information sources
A university librarian will assist the research team in the
development of the search strategy, and this librarian
will undertake the database searches. The following da-
tabases will be searched for reports of trials of exercise
training in persons with MS: Ovid MEDLINE All, Ovid
Embase, ProQuest PsycINFO, Cochrane Central Register
of Controlled Trials (CENTRAL), Ebsco CINAHL, Sco-
pus, Web of Science Core Collection (CC), and PEDro–
Physiotherapy Evidence. All databases are recommended
as core database for our field on inquiry [48].
Search terms will include free text keywords and rele-
vant subject headings, and there will be no language re-
strictions in the automated search (we will remove non-
English language articles during article screening). All
databases will be searched from 2013 to present, follow-
ing completion of the search in November 2013 for our
original review. As the relevant search engines do not
allow a search of exact months, we will hand search any
relevant publications from 2013 to ascertain if published
in November/December 2013. Supplementary material 1
comprises the proposed Medline search strategy.
We will further search the reference lists of included
studies and relevant systematic reviews for studies meet-
ing our inclusion criteria. Further, to identify the most
recent data, we will (1) search international clinical trial
registers for recently completed trials, including the Aus-
tralian and New Zealand Clinical Trials Registry, Euro-
pean Union Clinical Trials Register (EudraCT),
International Standard Randomised Controlled Trial
Number, US Clinical Trials Register, and the WHO Por-
tal, and make attempts to identify published studies (e.g.,
contacting authors); (2) we will use Scopus and Web of
Science to undertake forward citation searches for stud-
ies which fit our inclusion criteria; we will use the stud-
ies identified in our primary search and selection
criteria, above, as the base of our forward citation search;
(3) we will run our search strategy prior to submission
of our manuscript for publication.
Data management and extraction
Data will be managed during the screening and data ex-
traction process using Covidence (https://www. covi-
dence. org) and Microsoft Excel. Two review authors
will independently screen the titles and abstracts of
search results for relevance; we will acquire full texts of
relevant articles, and two review authors will then screen
these for relevance independently. Where full text can-
not be acquired, we will contact the authors of relevant
studies and request published or draft manuscripts.
Throughout the process, a third author will assist in re-
solving screening conflicts.
Data, described in Table 1, will be extracted from rele-
vant articles by two authors working independently.
Data will be extracted into a study-specific database
(Microsoft Excel file), and we will include a data diction-
ary and instructions for extracting researchers. Extract-
ing researchers will receive training and pilot the
database with a minimum of four studies each prior to
formal extraction. Discrepancies will be resolved by ad-
judication by raters after any necessary recoding.
Risk of bias
Two authors will independently assess study quality, via
risk of bias, in the studies, per the PEDro scale [49]. The
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use of the PEDro tool will (1) cement comparison be-
tween pre-2014 and contemporary studies and (2) allow
an overall narrative comment on reporting and study
quality in studies reporting safety data. This data will be
entered into the aforementioned database. Descriptive
domains in the PEDro tool assess the external validity of
the results (i.e., eligibility criteria) and the quality of the
trial (i.e., randomisation, concealed group allocation,
baseline similarities of groups, subject blinding, therapist
blinding, assessor blinding, key outcomes attained from
85% of the sample, intention to treat analysis, statistics
compared for at least one key outcome, and statistics
compared at more than one time-point). Consistent with
the literature on the use of the PEDro rating mechanism
[49], we will score each study on 10 of the 11 criteria,
with the criterion involving eligibility criteria not being
included in the overall score. We will categorise higher
quality studies as studies with a PEDro score of ≥ 6 and
lower quality studies as studies with a PEDro score of <6
[49]. We will judge the rater agreement on study quality
with Kappa [50]. Discrepancies will be resolved by adju-
dication by raters after any necessary recoding.
Outcomes
The primary outcomes of interest for the review are (1)
relapse, (2) AE, and (3) SAE. Secondary outcomes are
(4) dropout/retention and (5) adherence/compliance.
We define all terms in Table 1.
Per group, we will quantify the number of relapses
and, separately, the number and type of AE and SAE.
Reporting AE and adverse effects together will allow
comparison between previous results [35] and those re-
ported in studies published after November 2013. We
will provide a descriptive analysis and narrative descrip-
tion of adverse effects and serious adverse effects where
possible. Similarly, we will report retention as the num-
ber of completing participants per groups. We will pro-
vide descriptive data on adherence and compliance to
the intervention, in the intervention groups only.
We will undertake a narrative synthesis and critical ap-
praisal based on the risk of bias per PEDro scores, and
we will make a narrative comment on the difference in
safety reporting based on study quality. We will further
consider a narrative synthesis of participant characteris-
tics (e.g., type of MS and years since diagnosis) to de-
scribe and identify the clinical and policy implications of
our findings.
Analysis
Analyses will be conducted using SPSS (IBM SPSS v24;
MeanES and MetaReg macros) and Stata (Stata Corp
v14; meta).
Calculation of relative risk
Overall, we will calculate the relative risk of each of our
three primary outcomes and retention into the study
compared with control conditions. The unit of analysis
for each of our three outcomes is the total number of re-
lapses, adverse events, or serious adverse events experi-
enced in each group of each study. For example, the
overall rate of relapse, defined as the total number of re-
ported relapses in the exercise and control conditions
(i.e., number of relapses in each condition by the total
number in each condition), will be pooled across all
studies, respectively. We will calculate the overall rela-
tive risk of relapse using standard risk procedures, that
is a ratio of rates, or the ratio of participants in a treat-
ment group who experience an illness, condition, or
event (i.e., relapse) to those in a control group who ex-
perience the same illness, condition, or event [51]. We
will calculate relative risk by dividing the overall rate of
relapse, AEs, SAEs, or dropout for exercise by the overall
rate of relapse, AEs, SAEs, or dropout, respectively, in
the control condition. A relative risk of 1.0 would indi-
cate no difference in risk of the outcome between exer-
cise and control conditions. A relative risk above 1.0
would indicate a higher risk of events with exercise
training, and a relative risk below 1.0 would indicate a
lower risk of events with exercise training. We will only
report data from studies that directly report on the pres-
ence or absence of relapse or events. We will use stand-
ard procedures [52] to calculate relative risk, its standard
error, and 95% confidence interval. Where zeros create
problems with computation of relative risk or standard
errors, we will add 0.5 to all cells (e.g., exercise relapse,
exercise non-relapse, control relapse, and control non-
relapse) [53, 54].
Data synthesis and analysis
Using an SPSS MeanES macro [55], a random-effects
model will be used to aggregate mean relative risk for
each of the primary outcomes. Based on established
methods [56], we will calculate Cochrane Q and I2 to
evaluate heterogeneity and consistency, respectively. In
addition, sampling error will be calculated using
Cochrane’s Q according to established methods; hetero-
geneity will be indicated if sampling error accounts for
less than 75% of the observed variance and when p<0.05
for Q [57]. I2 values of 25%, 50%, and 75% will indicate
small, moderate, and large amounts of heterogeneity, re-
spectively [51]. Forest plots will be generated to illustrate
the distribution of each effect size weighted by its in-
verse variance. Funnel plots will be generated and visu-
ally inspected, and Egger’s regression [58] and Begg’s
rank correlation will be conducted to examine risk of
publication bias [58]. The number needed to treat for an
additional harmful outcome (NNTH), expressed as a
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function of absolute risk, will be calculated to express
the number of participants engaged in exercise training
for which one additional adverse outcome (i.e., relapse,
AE, SAE, or dropout) may be expected [59].
Random-effects models will be used to calculate the
mean relative risk and 95% CIs for each level of moder-
ator variables [55] or potential sources of variability in
the mean relative risk that are of logical, theoretical,
and/or prior empirical relation to exercise training
among persons with MS. Where data permits (i.e., where
there are three or more effects for levels of the moder-
ator variable), moderators will be included in random-
effects univariate meta-regression analysis with max-
imum likelihood estimation using the SPSS macro
MetaReg [55]. Meta-regression offers the benefit of con-
current estimates of independent effects by multiple
moderators on the variation in relative risk across trials.
Tests of the regression model (QR) and its residual error
(QE) will be reported. If meta-analysis is not possible for
a given outcome based on fewer than three effects, a
narrative synthesis of included study results will be per-
formed that appraises reported outcomes, study charac-
teristics and methodological procedures which may have
contributed to reported results, and the quality of in-
cluded studies.
Discussion
Our updated review of the safety of exercise interven-
tions in MS will pool relapse, AE, and SAE events in
RCTs published since November 2013. Since 2013, there
has been a dramatic increase in the number of clinical
exercise studies in MS [9] and a change in study design,
for example, exercise intervention type (e.g., vigorous in-
tensity interval training) [37] and intervention delivery
(e.g., remotely supervised exercise training). This high-
lights a need to further clarify safety. In addition, since
the publication of minimal exercise guidelines for exer-
cise in MS in 2013 [19, 29], there is a need to make
comment on the comparative safety reporting in studies
prescribing these guidelines. Focal review of interven-
tions delivering the exercise guidelines has not been
undertaken; this is fundamental to the clinical promo-
tion of these guidelines. We will compare previous lit-
erature on exercise training safety in MS [35–37], and
with our planned review of retention rates, intervention
adherence rates, and intervention compliance rates, we
will confirm recent meta-analyses [40]. Our protocol
provides a systematic and robust approach to determin-
ing the safety of exercise training in a clinical population
and has high utility for repetition in other clinical popu-
lations such as stroke, Parkinson’s disease, and other
populations where exercise prescription is a manage-
ment strategy.
This review will be the first to consider exercise train-
ing safety when comparing participant characteristics
(i.e., disability level). Identification of exercise training
safety will be informative for persons with MS, for clini-
cians, and MS advocacy groups when providing lifestyle
behaviour recommendations, for clinicians and re-
searchers when considering intervention delivery and de-
sign, and for funding bodies and policy-makers when
considering the impact of research applications.
Limitation of this systematic review and meta-analysis
include the potential heterogeneity of research method-
ology that we expect to find in the included studies
which will impact our choice of data analysis. In
addition, reporting of outcomes may limit possible ana-
lyses. Where our planned analyses are inappropriate, we
will proceed with narrative synthesis. We will report any
deviation to the protocol in the full review.
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